July 12th 2021, 1:52pm
Darzalex Faspro has received FDA approval for use in combination with pomalidomide and dexamethasone for patients with multiple myeloma who previously received one line of therapy.
July 1st 2021, 1:30pm
Donald Rumsfeld, who died from multiple myeloma, served as secretary of defense under Presidents Gerald R. Ford and George W. Bush.
June 24th 2021, 1:00pm
Recent findings merit further study of the immunosuppressive drug as therapy in patients with multiple myeloma.
June 22nd 2021, 9:00pm
Results from a recent study strongly support a treatment regimen of Darzalex with Revlimid and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.
June 11th 2021, 1:00pm
Treatment with an investigational drug induced high response rates in patients with relapsed or refractory multiple myeloma.
June 8th 2021, 9:00pm
Patients with relapsed/refractory myeloma who were previously treated with three or more therapies responded to an infusion of a novel CAR-T cell therapy up to 18 months with no new side effects compared with 12-month results of this study.
June 8th 2021, 6:30pm
The study’s lead author noted that a survival outcome, along with other results, was similar among the two groups.
June 6th 2021, 8:00pm
After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.
June 5th 2021, 8:00pm
A single infusion of a novel CAR-T cell therapy was associated with early and deep responses to treatment among a certain group of patients with multiple myeloma.
June 2nd 2021, 4:09pm
Donna and Dr Gasparetto close the discussion by highlighting the importance of physicians utilizing their patients, as well as patients being involved with their multiple myeloma treatment.
FDA’s Approval of Keytruda-Based Regimen for Certain Stomach Cancer Subtypes ‘Really Exciting’ For Patients
Heart Failure May Increase Cancer Risk
Easing Worried Patients During Difficult Times Throughout Cancer Treatment
A Trail of Crumbs
